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Abstract
Background: Published economic assessments of rotavirus vaccination typically use modelling, mainly static Markov cohort
models with birth cohorts followed up to the age of 5 years. Rotavirus vaccination has now been available for several years
in some countries, and data have been collected to evaluate the real-world impact of vaccination on rotavirus
hospitalisations. This study compared the economic impact of vaccination between model estimates and observed data on
disease-specific hospitalisation reductions in a country for which both modelled and observed datasets exist (Belgium).
Methods: A previously published Markov cohort model estimated the impact of rotavirus vaccination on the number of
rotavirus hospitalisations in children aged ,5 years in Belgium using vaccine efficacy data from clinical development trials.
Data on the number of rotavirus-positive gastroenteritis hospitalisations in children aged ,5 years between 1 June 2004
and 31 May 2006 (pre-vaccination study period) or 1 June 2007 to 31 May 2010 (post-vaccination study period) were
analysed from nine hospitals in Belgium and compared with the modelled estimates.
Results: The model predicted a smaller decrease in hospitalisations over time, mainly explained by two factors. First, the
observed data indicated indirect vaccine protection in children too old or too young for vaccination. This herd effect is
difficult to capture in static Markov cohort models and therefore was not included in the model. Second, the model
included a ‘waning’ effect, i.e. reduced vaccine effectiveness over time. The observed data suggested this waning effect did
not occur during that period, and so the model systematically underestimated vaccine effectiveness during the first 4 years
after vaccine implementation.
Conclusions: Model predictions underestimated the direct medical economic value of rotavirus vaccination during the first
4 years of vaccination by approximately 10% when assessing hospitalisation rates as compared with observed data in
Belgium.
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Introduction
The economic assessment of the newer rotavirus vaccines
(RotarixH [Rotarix is a registered trade mark of the GlaxoSmith-
Kline group of companies] and RotateqTM [Rotateq is a trademark
of Merck & Co. Inc.]) at the time of their first introduction in 2006
was largely model-based, in the absence of long-term data on
vaccine effects [1–3]. Most assessments at that time used static
Markov cohort models instead of dynamic models [4], which
simplified the model construction, the number of assumptions
introduced, and the data requirements [5]. Cohort models analyse
the vaccine situation at epidemiological steady-state [6] when
vaccination is already well established in the population at risk,
children less than 5 years old in the case of rotavirus. More
recently, there has been a shift towards developing more complex
models for estimating the total benefit of rotavirus vaccines
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because a herd effect after vaccination has been reported from
observational data [7–10].
Observational studies have shown that rotavirus infection
produces partial immunity after each exposure [11,12], with
complete immunity acquired after three to four infections. This
partly explains the peculiar distribution of rotavirus disease as a
function of age, which forms a bell-shaped curve during the first
two years of the birth cohort. A Markov cohort model can
replicate the natural history of rotavirus disease in a birth cohort
over time, with the highest disease burden occurring in children
aged between 6 months and 2 years, followed by a sharp decline
up to the age of 5 years, after which natural immunity across the
cohort is maintained.
The early economic models of rotavirus vaccination included
much uncertainty due to the many unknowns in the data available
at the time, such as the impact of rotavirus disease on quality-
adjusted life-years (QALY), waning of vaccine efficacy over time
(presumed from clinical trials), and the proportion of rotavirus
gastroenteritis cases who do not seek medical care [13]. Such
unknowns were modelled using ‘best-guess’ baseline assumptions,
tested in sensitivity analyses to evaluate their impact on the
incremental cost-effectiveness ratio (ICER).
Among these unknowns, vaccine waning is of particular interest.
Vaccine efficacy in the cohort models was derived from clinical
trial results for the rotavirus vaccines. The trials indicated higher
vaccine efficacy against rotavirus diarrhoea during the first year
than in subsequent years [14]. However, it should be noted that
the decrease in vaccine efficacy measured over time in the
European trial was mainly due to a large reduction in rotavirus
diarrhoea events reported in the non-vaccinated arm (242%),
rather than due to an increase in the numbers of events in the
vaccinated arm as one would expect from vaccine waning over
time. This indicated that the vaccine waning assumption in the
early models should be re-examined.
The two rotavirus vaccines have now been in use for several
years, and real-life data are becoming available. A few follow-up
studies after vaccine introduction provide information on real-life
vaccine effectiveness on specific mortality reduction in Mexico and
hospitalisation rates in Brazil, US, Australia and some European
countries [15–22]. It is now possible to test whether the model-
predicted results presented at the time of the product launch were
accurate enough to report reliable cost-effectiveness data. Clearly,
should substantial discrepancies occur between prediction and
observation, understanding the possible causes would be valuable
to improve the next generation of vaccine models. Few attempts
have yet been made in the published literature to compare results
predicted by models at vaccine introduction with real-life data
observed over time.
Belgium provides a good opportunity to conduct such a
comparison for rotavirus vaccination, as modelled estimates and
observed data from a follow-up study of four years post-
vaccination and two years pre-vaccination are available [18,23].
In a previous paper on the impact of rotavirus vaccination on
hospitalisation in Belgium, we reported that the observed
reductions in rotavirus hospitalisations after vaccine introduction
were greater than those predicted by modelling [18]. In the
present analysis, we have explored this discrepancy further using
the most recent data from the observational study (up to four years
post-vaccination) to identify potential reasons for the differences,
and have adjusted the modelled ICER for differences between
predicted and observed data.
Methods
Model construction
When rotavirus vaccination was introduced in Belgium in 2006,
a Markov cohort model, mainly based on the model published by
Melliez et al. [23,24], assessed at vaccine steady-state the rate of
rotavirus acute gastroenteritis (AGE) in a birth cohort by month
up to the age of 5 years. The model included different
management options typical for the Belgian context such as
staying at home, seeking medical advice from a primary care
physician or a specialist, visiting the emergency room, or
admission to hospital. The distribution of rotavirus AGE cases
by age was constructed following a Weibull function [25]. A
Weibull distribution with its shape (k = 1.5) and scale (l= 24.2)
parameters allows replication of the distribution of rotavirus
disease as a function of age, influenced by the gradual
disappearance of maternal antibodies after birth and by new
rotavirus infections appearing over time that stimulate the
development of natural immunity. The two parameters should
be adjusted for country-specific data using calibration techniques
specifying breastfeeding behaviour and the frequency of infection
exposure over time.
Vaccine efficacy data used in the model were taken from a
European trial, which showed a decrease in effect over time that
differed between mild (staying at home), moderate (seeking
medical advice), and severe (hospitalised) cases [14].
For each level of disease severity, specific costs and utility scores
were applied [23]. The model compared vaccinated and
unvaccinated cohorts and allowed for changes in vaccine
coverage. Herd protection was not included. The model estimated
the vaccine effect on the number of AGE events, medical visits,
emergency visits, hospitalisations and deaths in a birth cohort of
children up to the age of 5 years. It also reported the overall cost,
QALY impact, and ICER for vaccination compared with no
vaccination.
Observational study
A vaccine impact study was set up one year after the
introduction of the rotavirus vaccine in Belgium [18,21]. Full
details and the results for the first two years post-vaccination (up to
May 2009) have been published elsewhere [18]. Data were
collected retrospectively after each rotavirus season from a sample
of 12 Belgian hospitals. All children aged #5 years who had a
rotavirus detection test performed at a participating hospital from
1 June 2004 to 31 May 2006 (pre-vaccination study period) or 1
June 2007 to 31 May 2010 (post-vaccination study period) were
eligible. Only hospitalised children were included, and data were
analysed for the nine centres with a complete dataset. Ethical
approval was not required because there was no medical file
consultation.
The post-vaccination study period was divided into successive
years, each running from June to May (June 2007–May 2008, June
2008–May 2009 and June 2009–May 2010) to cover the winter
rotavirus season. The period between 1 June 2006 and 31 May
2007 was not included in our study, because reimbursement for
rotavirus vaccination was not available for the whole of this period
(partial reimbursement was introduced in Belgium in November
2006 for RotarixH and in June 2007 for RotaTeqTM [18]). Thus,
although June 2006–May 2007 could be considered as the first
year post-vaccination, the date of reimbursement meant that it was
neither fully pre-vaccination nor fully post-vaccination. In this
study we therefore analysed data from the second post-vaccination
year (June 2007–May 2008) onwards. For each year the number
and the proportion of rotavirus-positive episodes were calculated
Modelled and Observed Rotavirus Vaccination Data
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per week. Hospitalisation was classified as AGE-driven if the stool
sample was collected within 48 hours of hospitalisation. The most
relevant variable to compare in the pre- and post-vaccination
periods is the absolute number of rotavirus-positive episodes
observed, assuming no change in catchment area between the
study periods for each participating hospital.
Comparison between observed and modelled data
From the raw observed data we first calculated the frequency of
hospitalisation per week for each of five age groups (0–1 year; 1–2
years; 2–3 years; 3–4 years; 4–5 years) over a period of one year
for the pre-vaccination period and for the second (June 2007–May
2008) and fourth (June 2009–May 2010) years post-vaccination. As
the data are from a small sample, it is likely that data from a larger
sample would follow a smoother distribution. This is represented
by adjusting the raw frequencies to smoothed parametric curves
using @RISK 5.7 software (Palisade Corporation, US). The
software is an add-in program in Microsoft ExcelH that uses the
collected data as input variables, for which it creates a distribution
expressed as a probability density function from a list of around 20
continuous parameterised distributions. Since all probability
distribution functions must have a unit area, the software
automatically scales the probability values so that the density
curve has an area of one. The method of least squares is used to
minimize the Root-Mean Square Error between the curve points
and the theoretical distribution function selected (RMS Error
value ,0.05 or the best Chi-squared statistics noted between the
observed data and selected parametric distribution). The figures
obtained are referred to in this paper as smoothed curves, or
adjusted observational data. Because the smoothed curves are
parameterised distributions, they are easier to work with when
calculating values for the areas under curves.
The original modelled data were derived from a hypothetical
birth cohort followed over time from birth to age 5 years, whereas
the observed data were derived from multiple one-year cross-
sectional observations in a population of children aged up to 5
years. To allow a transparent comparison between the two, it was
necessary to transform the results from the cohort model to a
population approach, which could be compared with the
population data from the observational study.
This transformation includes as a first step elaborating the
original single cohort model into a multiple cohort model with five
birth cohorts, sequencing the start by delaying each subsequent
year. This construction allows the vaccine coverage rate and the
vaccine efficacy to be varied by month, year, and age group.
Vaccine efficacy and coverage values are shown in Table 1. The
baseline age distribution for rotavirus AGE events in each cohort
model followed a Weibull function as described above. The age
distribution for hospitalised events used a modified distribution to
take into account the higher hospitalisation rate in infants and
young children. The parameter values used in each Weibull
distribution are shown in Table 1. The net hospital age-
distribution result in each cohort model was the combination of
the two distributions, multiplying the density probability function
of the AGE distribution by the hospitalisation distribution, leading
to a combined distribution (Figure 1).
The next step was to introduce two assumptions in the analysis
that could be checked against the observed data. First, we assumed
that the annual epidemic rotavirus spread of hospitalised disease in
children aged up to 5 years followed a normal distribution.
Registry data on the annual spread of rotavirus indicate that this
assumption is acceptable [26]. We therefore constructed a normal
distribution over a 52-week period with a standard deviation of
0.16 for a mean value of 1, by which the spread of the disease is
absent over a period of 16 weeks per year. The second assumption
was that the age distribution per week in the normal distribution
followed the combined distribution of the age cohort, as defined in
Table 1. As a consequence, the disease spread each year appeared
first and disappeared last in infants and young children, compared
with older children, reflecting the distribution with a higher
hospitalisation rate in infants and young children.
This approach allowed precise measurement of differences
between the impact of vaccination in the model construct and the
observational data. Any differences identified between the
observation and the modelled results were explored to see if
potential explanations could be found. Once potential explana-
tions were identified, we adjusted the model input values to be
equivalent to the observed data to estimate adjusted ICERs.
Results
Figure 2 shows the pre-vaccination curves for adjusted observed
data on the number of hospitalisation events by week and age
group (Figure 2A) that were similar to the modelled results from
the multiple age-cohort model (Figure 2B). As expected, the pre-
vaccination peak in rotavirus hospitalisations was highest in
children aged ,1 year. In the observed data the peak appeared at
approximately the same time of the year (Week 8) in all age
groups, consistent with seasonal rotavirus spread and indicating a
dependency in rotavirus transmission between age groups. The
two assumptions introduced into the multiple cohort model to
construct a population approach appeared to hold when
comparing the distribution results of the model and the
observation data. Moreover, there was close agreement between
the observed and modelled numbers of rotavirus hospitalisations
by age group per year for the pre-vaccination scenario (Table 2).
In the post-vaccination period, the observed data showed that
the seasonal peak in rotavirus hospitalisations was reduced in
magnitude and delayed (shifted to the right) in the second year
after vaccine introduction for the first two age groups, with further
reduction and delay in the fourth year across all age groups
(Figure 3A–D).
As the observational study included children aged up to 5 years,
some of the children enrolled in the post-vaccination period were
too old for vaccination when the vaccine was introduced, and thus
were unvaccinated. The age threshold increased in successive
Figure 1. Probability density functions for defining hospital-
isation rate as a function of age (pre-vaccination). Diarrhoea
events, distribution of rotavirus AGE events as a function of age from
birth to age 60 months (5 years); Hospitalisation, distribution of
hospitalised rotavirus events from birth to age 60 months (5 years);
Combined. combined function.
doi:10.1371/journal.pone.0053864.g001
Modelled and Observed Rotavirus Vaccination Data
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years post-vaccination. In the second year post-vaccination (June
2007–May 2008), the maximum age of vaccinated children was 21
months (born in or after September 2006, just in time to receive
vaccination after reimbursement of the first rotavirus vaccine
product in November 2006, and included in the last month of that
study year in May 2008), and in the fourth year post-vaccination
(June 2009–May 2010) the maximum age of vaccinated children
was 45 months (born in or after September 2006 and included in
the last month of that study year in May 2010). The reduction in
hospitalisations post-vaccination compared with pre-vaccination
observed in the age groups who were too old to be vaccinated
(Table 3), indicated that the vaccine had an indirect protective
effect.
There is a second group of children ineligible for vaccination,
those too young to receive the vaccine (aged up to 2 months). The
number of observed rotavirus gastroenteritis events in this age
group also declined in the years after vaccine introduction (Table 4)
(Chi-square-test for trend, p,0.01). The results indicated that a
herd protection effect may also occur in children too young for
vaccination, due to reduced transmission of natural rotavirus
infection after vaccine introduction.
The overall herd effect that occurred in real life was not
included in the model. But the more rapid decrease in
hospitalisations in the observed data, compared with the model,
is also noteworthy because the model assumed a decrease in
vaccine efficacy year on year (Table 1), which was not apparent in
the observed data. In sensitivity analysis, the model was run with
no decrease in vaccine efficacy (i.e. assuming that vaccine efficacy
was the same in subsequent years as in the first year). These data
Table 1. Model-specific adaptations to fit pre-vaccination observed data.
Parameter Value
Disease distribution as a function of age from birth to month 60 Weibull 1 with parametric distribution of k = 1.5 and l=24.2
Hospitalisation distribution as function of age from birth to month 60 Weibull 2 with parametric distribution of k = 0.6 and l=29.3
1st year vaccine coverage 60%*
2nd year vaccine coverage 80%*
3rd year vaccine coverage 85%*
4th year vaccine coverage 85%*
Estimated vaccine efficacy 1st year 95%
Estimated vaccine efficacy adjustment every subsequent year post-vaccination (reduction in
efficacy to represent vaccine waning)
15% per year
*reported from Intercontinental Medical Statistics (IMS) data.
doi:10.1371/journal.pone.0053864.t001
Figure 2. Observed and modelled numbers of hospitalised
rotavirus events (pre-vaccination). Adjusted observed data
(smoothed curves) by age group (A); Results by age group from the
multiple age-cohort model (B). Weeks are numbered according to
seasonal distribution.
doi:10.1371/journal.pone.0053864.g002
Table 2. Reported hospitalisation events over one year by
age group pre-vaccination, for observed and modelled data.
Number (%) of rotavirus hospitalisations
Age group (years) Observed Modelled
,1 454 (51.8%) 439 (49.8%)
1–2 319 (36.2%) 312 (35.4%)
2–3 86 (9.7%) 106 (12.0%)
3–4 15 (1.7%) 21 (2.4%)
4–5 7 (0.8%) 3 (0.3%)
Total 880 881
doi:10.1371/journal.pone.0053864.t002
Modelled and Observed Rotavirus Vaccination Data
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Figure 3. Impact of rotavirus vaccination after 2 and 4 years of vaccination by age group (observed data). Aged ,1 year (A); Aged 1–2
years (B); Aged 2–3 years (C); Aged .3 years (D). Weeks are numbered according to seasonal distribution.
doi:10.1371/journal.pone.0053864.g003
Table 3. Observed and modelled data pre- and post-vaccination by year and age group.
Post-vaccination % reduction from pre-vaccination
Age group (years) Pre-vaccination Year 2 Year 4 Adjusted Year 2 Year 4 Adjusted
Observed
,1 454 125 77 72% 83%
1–2 319 164 72 49% 77%
2–3 86 61 17 29% 80%
3–4 15 9 10 40% 33%
4–5 7 9 3 229% 57%
Total 880 368 179 58% 80%
Modelled
,1 439 146 127 127 67% 71% 71%
1–2 312 161 111 73 48% 64% 77%
2–3 106 106 48 29 0% 55% 73%
3–4 21 21 11 7 0% 48% 67%
4–5 3 3 3 3 0% 0% 0%
Total 881 437 300 239 50% 66% 73%
Number of rotavirus hospitalisations from observed and modelled data. Adjusted data refer to modelled data with vaccine waning removed from the model (i.e.
assuming that vaccine efficacy is the same in subsequent years as in the first year).
doi:10.1371/journal.pone.0053864.t003
Modelled and Observed Rotavirus Vaccination Data
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are shown in Table 3 and Figure 4 as ‘Adjusted’ data. They closely
followed the observed data for the fourth year post-vaccination.
The estimated ICER for rotavirus vaccination was based on the
modelled data at the time of vaccine introduction. Our earlier
results [18] indicated that the model underestimated the reduction
in hospitalisation rates. Our present results show that herd effect
on the one hand, and lack of waning on the other, were the main
differences between the original static model and real-life data
(Figure 3, Tables 3 and 4). Adjusting the model for these factors
produced an estimated ICER slightly more favourable to rotavirus
vaccination than the estimated ICER without these adjustments
(Table 5). The change in the ICER was small (approximately a
10% improvement), because the major impact of change was
mainly measured two years after vaccine introduction when the
hospitalisation rate was already reduced. The ICER was
calculated from the perspective of the healthcare system (direct
medical costs only), and so did not capture some categories of cost
such as lost productivity from parents taking time off work to look
after a sick child. Such costs were not included because we were
unable to collect data on them in a real-life setting. A further
reduction in the ICER would be expected with an analysis
performed from a societal perspective capturing a wider range of
costs.
Discussion
This analysis compared observed data on rotavirus-related
hospitalisations collected in routine clinical practice for four years
post-vaccination in Belgium with previously modelled estimates of
the effect of vaccination in the same country. The observed
reduction in hospitalisations with data from two years post-
vaccination has previously been shown to exceed the reduction
predicted by the static model [18]. Two differences between the
modelled and the observed data were identified that could explain
this discrepancy. First, the observed data indicated an indirect
herd effect in infants too young (aged ,2 months) and too old for
vaccination when the vaccine was introduced, which was not
included in the model. Second, the model assumed a waning of
vaccine efficacy over time based on clinical trial data, which did
not appear to be reflected in the observed data from a real-life
situation over time frames of three or four years.
Regarding waning of vaccine efficacy, analysis of the vaccine
efficacy results of the European trial may offer an explanation that
better helps in understanding the difference between the modelled
and the observed data. Vaccine efficacy is normally measured as
the proportion of one minus the ratio of events that appear in the
study arm that received the vaccine divided by the number of
events that occur during the same time interval in the non-
interventional arm. When analysing the vaccine efficacy in the first
and subsequent years of the trial, researchers assume that if a
dramatic decrease in events occurs in the non-interventional arm
in the second year compared with the first year, as seen in the
European trial (the decrease observed in the first versus subsequent
year is .40%), a similar decrease should also be observed in the
vaccinated arm on top of the measured vaccine benefit of the first
year. Any deviation from this result is explained as a reduction in
vaccine efficacy called vaccine waning. This assumption is hard to
accept as the explanation. The absolute number of events in the
vaccinated group during the second year amounted to about the
same values as in the first year. So, most of the decrease in vaccine
Table 4. Rotavirus hospitalisations pre- and post-vaccination in infants ,3 months old.
Number of rotavirus hospitalisations
Age group Pre-vaccination Post-vaccination second year Post-vaccination third year Post-vaccination fourth year
0-1 month 18 12 4 6
1-2 month 46 8 13 11
2-3 month 38 23 14 6
(Chi-square for trend: p,0.001).
doi:10.1371/journal.pone.0053864.t004
Figure 4. Pre- and post-vaccination data by year and age
group. Observed data (A); Modelled data (B). Pre-vac, pre-vaccination;
Post-vac2, second year post-vaccination; Post-vac4, fourth year post-
vaccination; Adjusted, modelled results assuming no vaccine waning,
included for comparison purposes.
doi:10.1371/journal.pone.0053864.g004
Modelled and Observed Rotavirus Vaccination Data
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efficacy in the second year in the trial was due to a sharp decrease
in the number of events in the denominator, rather than to a sharp
increase of the numbers in the vaccinated arm. We hypothesise
that the results in the non-interventional arm could have been
influenced by a herd effect in the trial, because the randomisation
process included 2 vaccinated children for 1 non-vaccinated child.
This 2:1 randomisation may have further decreased the number of
events in the non-vaccinated arm in the second year of the trial. As
a result of this observed evidence – a large imbalance in the
number of events observed over time in the non-vaccinated arm –
the true vaccine efficacy measured in the trial may be an
underestimate compared with vaccine effectiveness observed in
real life, as seen here in the impact study results. It is of interest
that the decrease in the subsequent year seen in the 2:1
randomised trial (.40%) was greater than that observed in a 1:1
randomised trial of rotavirus vaccination conducted in the US,
where the reduction from the first year to the second was
approximately 15% [27].
Even if we introduce a correction into the model by excluding
the waning scenario (adjusted results in Table 3), the model still
underestimates the total vaccine benefit, mainly because of the
indirect protection in infants too young to be vaccinated (aged ,2
months). This can be seen in Figure 4, where the change in
number of hospitalisations between pre-vaccination and the
second and fourth years post-vaccination in children aged ,1
year was considerably larger in the observed data (Figure 4A) than
in the modelled data (Figure 4B). The indirect vaccine efficacy
seen in these very young infants is likely to remain at steady-state
level. This analysis also provides indirect information about
rotavirus transmission in children. Since rotavirus vaccination
appeared to have an indirect protective effect on young infants,
our results suggest that children in the age range eligible for
vaccination can infect younger children.
If vaccination alters the natural transmission of rotavirus in the
population outside the at-risk group, it is possible that an age-shift
of rotavirus disease could occur, as predicted by dynamic models
[7]. However, if the wild-type rotavirus still circulates in the whole
population, allowing reinfection and boosting of natural immunity,
age-shifts of rotavirus disease may be less likely to happen after
introducing vaccination. It is not yet known how rotavirus
vaccination will affect rotavirus transmission. It is, however, likely
that reported observations over longer time periods will see less
important herd effects per year than observed here as soon as the
whole at-risk population (children aged ,5 years) has been
vaccinated.
Our analysis of the observed data suggests that no reduction in
vaccine efficacy (vaccine waning) occurred in real life during the
first 4 years. It is known that subjects repeatedly exposed to
rotavirus gradually build up natural immunity over time. This has
been well illustrated by Velazquez and colleagues [28] and others
[29]. The observed age-related disease pattern (more cases in
young children than in older ones) reflects this immunity build-up,
together with other factors that could affect exposure such as
behaviour changes. Therefore the effect measured in a clinical trial
is not only the vaccination effect, but is a difference between
vaccinated and unvaccinated groups (which can be called a net
effect) (Figure 5). As natural immunity develops over time in the
non-vaccinated group, the net effect would change over time, and
that could be mistakenly interpreted as vaccine waning. Herd
protection effects could influence the change in net effect as
natural immunity would be larger in its absence (because exposure
to the virus would be larger).
The results presented in this paper indicate that the ICER
estimated from the model for vaccination versus no vaccination,
using vaccine efficacy results from randomised controlled trials,
may have underestimated the benefit of rotavirus vaccination.
Adjusting for that difference would result in a model outcome
more closely related to the observed data. The effect is marginal
from a healthcare system perspective, as the benefit is mainly seen
after two years of vaccine exposure when hospitalisation rates are
already low. However, it may have a larger impact on the ICER
considered from a societal perspective. We conducted a simulation
exercise to explore the potential effect if the reduction in
hospitalisations observed in this study were also to occur across
the whole disease management area of non-hospital medical visits
and indirect costs. If non-hospital medical visits and indirect costs
are reduced by the same amount as observed for hospitalisations,
the ICER results estimated by the model would improve by
Figure 5. Natural immunity and immune response after
vaccination, showing the net effect of vaccination (arrow line).
doi:10.1371/journal.pone.0053864.g005
Table 5. Cost-effectiveness of rotavirus vaccination pre- and post-adjustment.
Cost Difference QALY Difference ICER
Pre-adjustment
No vaccination 70 J 20.002
Vaccination 139 J 69 J 20.00063 0.00138 51 000 J [23]
Post-adjustment
No vaccination 70 J 20.002
Vaccination 135 J 65 J 20.00055 0.00145 44 828 J (210%)
ICER, Incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
doi:10.1371/journal.pone.0053864.t005
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.30%. Collecting real-life data on non-hospital medical visits and
indirect costs to test this prediction would be a valuable area for
future research. This finding will of course be country-specific,
depending on the specific disease management programmes in
place and whether the economic assessment is conducted after
reaching the steady-state level.
In conclusion, it is likely that previously published economic
models underestimated the total benefit of rotavirus vaccination,
by not including an estimate of herd protection and by including a
vaccine waning effect that was not reflected in real-life conditions
during the first 4 years of vaccine introduction. These findings
could be applicable in other disease areas in which natural
immunity develops over time as a result of regular exposure to the
infectious agent, although this is not often observed. Static cohort
models have major difficulties in capturing such effects and may
therefore underestimate the total benefit of vaccines when
introduced in children.
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